Daniel A. Heller, PhD (Damon Runyon Fellow ’10-’12), and colleagues at Memorial Sloan Kettering Cancer Center, New York, reported that radiation-guided nanoparticles may offer a new approach for penetrating the vascular barrier that often prevents current nanomedicines from reaching metastatic tumors. In a mouse model of lung cancer and metastatic melanoma and breast tumors, the nanoparticles selectively delivered chemotherapy drugs to the tumors. The researchers hope to translate these findings to clinical trials. The study was published in Science Translational Medicine.
